Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis

Kenneth Blum, Alphonse Kenison Roy, Arwen Podesta, Edward J. Modestino, Bruce Steinberg, Marjorie C. Gondré-Lewis, David Baron, Panayotis K. Thanos, Lisa Lott, Sampada Badgaiyan, Jessica Valdez Ponce, Brent Boyett, David Siwicki, Mark Moran, Drew Edwards, Thomas McLaughlin, Eric R. Braverman, Thomas A. Simpatico, Mary Hauser, Bernard William DownsRajendra D. Badgaiyan

Producción científica: Chapter

3 Citas (Scopus)

Resumen

Reward Deficiency Syndrome (RDS) is an umbrella term for all drug and nondrug addictive behaviors, due to a dopamine deficiency, “hypodopaminergia.” There is an opioid-overdose epidemic in the USA, which may result in or worsen RDS. A paradigm shift is needed to combat a system that is not working. This shift involves the recognition of dopamine homeostasis as the ultimate treatment of RDS via precision, genetically guided KB220 variants, called Precision Behavioral Management (PBM). Recognition of RDS as an endophenotype and an umbrella term in the future DSM 6, following the Research Domain Criteria (RDoC), would assist in shifting this paradigm.

Idioma originalEnglish (US)
Título de la publicación alojadaThe Cambridge Handbook of Substance and Behavioral Addictions
EditorialCambridge University Press
Páginas297-306
Número de páginas10
ISBN (versión digital)9781108632591
ISBN (versión impresa)9781108427166
DOI
EstadoPublished - ene 1 2020

ASJC Scopus subject areas

  • General Psychology
  • General Social Sciences
  • General Medicine

Huella

Profundice en los temas de investigación de 'Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis'. En conjunto forman una huella única.

Citar esto